Abstract 57P
Background
Bile duct cancer (BDC) is a malignancy thought to be derived from cholangiocytes, the epithelial cells lining the biliary tree. BDC is a highly aggressive tumour whose incidence has been increasing worldwide over the past two decades, now accounting for 10–15% of all hepato-biliary malignancies. The mechanisms underlying cholangiocyte malignant transformation and BDC progression is still not completely understood. Genomic profiling can offer a clearer understanding of their carcinogenesis, classification and treatment strategy. We performed large-scale genome sequencing analyses on BDCs to identify novel key-genes driving BDC and drug-resistance.
Methods
We analyzed 100 BDC samples from an Italian Cohort, 40 by whole-exome sequencing, 80 by RNA sequencing, and a further 30 samples by SmallRNA sequencing. By using a bio-informatic pipeline, we integrated somatic mutation patterns and epigenetic features defined at the spatial level to identify novel target genes in the tumour microenvironment.
Results
A total of 3392 and 6315 DEGs (Differentially expressed genes) were respectively observed in BDC comparing tumour (T), normal (N) and stromal (ST) areas with the criterion of false discovery rate <0.05. In top-ranked differentially regulated gene sets, we identified primary cilium-associated genes (PC). OFD1, CNGB1, AURKA, CENPF, STIL, STK39, RAB23 and OSR1 were found based on the criteria of fold change >2.5 and P<0.01. We started also to clarify at molecular level the role of PC in BDC pathogenesis and progression. A therapeutic approach targeting OFD1 in BDC cells was also investigated.
Conclusions
Loss of PC is frequently observed in BDC, suggesting that the absence of this organelle may promote tumorigenesis through aberrant signal transduction and the inability to exit the cell cycle. We investigated the molecular mechanisms underlying the cilia loss and test whether may be potential therapeutic target. These findings could be useful to establish treatment and diagnostic strategies for BDCs based on genetic information.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AIRC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model
Presenter: Samer Salah
Session: Poster session 13
2010P - Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study
Presenter: Aleksander Antoniewicz
Session: Poster session 13
2011P - Neoadjuvant immunotherapy-driven bladder preservation for muscle-invasive bladder cancer: A multicenter, propensity score-matched cohort study
Presenter: Jiao Hu
Session: Poster session 13
2012P - Role of first-line immunotherapy in urothelial cancer with bone metastases: A national cancer database analysis of 3971 patients
Presenter: Zin Myint
Session: Poster session 13
2013P - First preliminary results of artificial intelligence generated treatment recommendations for urothelial cancer based on multidisciplinary cancer conferences from the KITTU project
Presenter: Gregor Duwe
Session: Poster session 13
2014P - Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
Presenter: Patrizia Giannatempo
Session: Poster session 13
2015P - Serum nectin-4: Prognostic and predictive value in bladder cancer?
Presenter: Kerstin Junker
Session: Poster session 13
2016P - Evaluation of event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) following neoadjuvant (NAD) therapy
Presenter: Cora Sternberg
Session: Poster session 13
2017P - Intrinsic molecular difference between bladder and upper tract urothelial carcinomas and its impacts in treatment response
Presenter: Jiwon Kim
Session: Poster session 13